Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequen...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Cancer J
Auteurs principaux: Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Hänel, Mathias, Dürig, Jan, Goldschmidt, Hartmut
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7791127/
https://ncbi.nlm.nih.gov/pubmed/33414374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00390-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires